Your search returned 40 results.

Results
	1.	Re: Patient and physician preferences for the treatment of chronic hepatitis C virus infections: does the perspective matter? (Eur J Gastroenterol Hepatol 2015, 27:1063-1068). [electronic resource] by Dintsios, Charalabos-Markos Producer: 20160525 In: European journal of gastroenterology & hepatology vol. 28 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Some essential clarifications: IQWiG comments on two critiques of the efficiency frontier approach. [electronic resource] by Dintsios, Charalabos-Markos Gerber, Andreas Producer: 20110103 In: Health economics vol. 19 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Determinants of Orphan Drug Prices in Germany. [electronic resource] by Worm, Franziska Dintsios, Charalabos-Markos Producer: 20210322 In: PharmacoEconomics vol. 38 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany. [electronic resource] by Herpers, Matthias Dintsios, Charalabos-Markos Producer: 20190618 In: The European journal of health economics : HEPAC : health economics in prevention and care vol. 20 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	A distorted picture of IQWiG methodology. [electronic resource] by Gerber, Andreas Dintsios, Charalabos-Markos Producer: 20110822 In: Health affairs (Project Hope) vol. 29 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	The impact of HTA reports on health policy: a systematic review. [electronic resource] by Gerhardus, Ansgar Dintsios, Charalabos-Markos Producer: 20110714 In: GMS health technology assessment vol. 1 Availability: No items available. Save to lists Add to cart (remove)
	7.	Confirmatory versus explorative endpoint analysis: Decision-making on the basis of evidence available from market authorization and early benefit assessment for oncology drugs. [electronic resource] by Niehaus, Ines Dintsios, Charalabos-Markos Producer: 20181126 In: Health policy (Amsterdam, Netherlands) vol. 122 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	8.	Arbitration Board Setting Reimbursement Amounts for Pharmaceutical Innovations in Germany When Price Negations between Payers and Manufacturers Fail: An Empirical Analysis of 5 Years' Experience. [electronic resource] by Ludwig, Saskia Dintsios, Charalabos-Markos Producer: 20170517 In: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 19 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	9.	INDUSTRY'S EXPERIENCES WITH THE SCIENTIFIC ADVICE OFFERED BY THE FEDERAL JOINT COMMITTEE WITHIN THE EARLY BENEFIT ASSESSMENT OF PHARMACEUTICALS IN GERMANY. [electronic resource] by Dintsios, Charalabos-Markos Schlenkrich, Sara Producer: 20181015 In: International journal of technology assessment in health care vol. 34 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	10.	Failure due to formal reasons within German benefit assessment of medicinal products: the dilemma between marketing authorization and HTA. [electronic resource] by Molitor, Markus Dintsios, Charalabos-Markos Producer: 20210408 In: Expert review of pharmacoeconomics & outcomes research vol. 21 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	11.	[Subgroups in the early benefit assessment of pharmaceuticals: a methodical review]. [electronic resource] by Rasch, Andrej Dintsios, Charalabos-Markos Producer: 20160120 In: Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen vol. 109 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	12.	Letter to the editor of the Journal of Affective Disorders: Supporting the guideline's quest for real direct costs of depression care. [electronic resource] by Dintsios, Charalabos-Markos Wagner, Christoph J Producer: 20180416 In: Journal of affective disorders vol. 208 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	13.	Re: "Early benefit assessment of new drugs in Germany--results from 2011 to 2012" [Health Policy 116 (2-3) (2014) 147-153]. [electronic resource] by Orben, Tina Rasch, Andrej Dintsios, Charalabos-Markos Producer: 20150917 In: Health policy (Amsterdam, Netherlands) vol. 118 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	14.	Information on ethical issues in health technology assessment: how and where to find them. [electronic resource] by Droste, Sigrid Dintsios, Charalabos-Markos Gerber, Andreas Producer: 20110216 In: International journal of technology assessment in health care vol. 26 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	15.	Reflections on the changing face of German pharmaceutical policy: how far is Germany from value-based pricing? [electronic resource] by Gerber, Andreas Stock, Stephanie Dintsios, Charalabos-Markos Producer: 20111007 In: PharmacoEconomics vol. 29 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	16.	Coated stents to prevent restenosis in coronary heart disease. [electronic resource] by Gorenoi, Vitali Dintsios, Charalabos-Markos Hagen, Anja Producer: 20110714 In: GMS health technology assessment vol. 1 Availability: No items available. Save to lists Add to cart (remove)
	17.	Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases. [electronic resource] by Schlander, Michael Dintsios, Charalabos-Markos Gandjour, Afschin Producer: 20180619 In: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 21 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	18.	[Patient participation in defining and assigning importance to treatment outcomes--status quo and potential developments]. [electronic resource] by Scheibler, Fülöp Scheike, Inger M Dintsios, Charalabos-Markos Producer: 20090427 In: Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen vol. 102 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	19.	Questioning patient subgroups for benefit assessment: challenging the German Gemeinsamer Bundesausschuss approach. [electronic resource] by Ruof, Jörg Dintsios, Charalabos-Markos Schwartz, Friedrich Wilhelm Producer: 20140825 In: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	20.	Quantified patient preferences for lifestyle intervention programs for diabetes prevention-a protocol for a systematic review. [electronic resource] by Dintsios, Charalabos-Markos Chernyak, Nadja Grehl, Benjamin Icks, Andrea Producer: 20190528 In: Systematic reviews vol. 7 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

Refine your search

Availability

Authors

Topics

Languages

Your search returned 40 results.